The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas.

##STR00001## wherein A is —(CH2).sub.a—CH═CH—(CH 2).sub.5-a—H where a is from 0 to 5, —(CH2).sub.b—CH═CH—(CH 2).sub.6-b—H where b is from 0 to 6, —(CH2).sub.c—CH═CH—(CH 2).sub.7-c—H where c is from 0 to 7, —(CH2).sub.d—CH═CH—(CH 2).sub.8-d—H where d is from 0 to 8, or —CH2).sub.e—CH═CH—(CH 2).sub.9-d—H where d is from 0 to 9; B is hydrogen or C.sub.1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

The present invention provides compositions for delivering cannabinoids to the nasal cavity. The subject invention utilizes a composition comprising one or more cannabinoids and an adjuvant mixture to enhance the delivery of the cannabinoid, benefitting the subject to whom the cannabinoid is delivered.

An anti-inflammatory liquid composition for covering oral mucosa includes: a rosin; a shellac; and a solvent. A content of the rosin is 1 wt % or more and 15 wt % or less relative to a total amount of the composition. A content of the shellac is 35 wt % or more and 45 wt % or less relative to the total amount of the composition. A total content of the rosin, the shellac, and a copal is 45 wt % or more and 55 wt % or less relative to the total amount of the composition.

An anti-inflammatory liquid composition for covering oral mucosa includes: a rosin; a shellac; and a solvent. A content of the rosin is 1 wt % or more and 15 wt % or less relative to a total amount of the composition. A content of the shellac is 35 wt % or more and 45 wt % or less relative to the total amount of the composition. A total content of the rosin, the shellac, and a copal is 45 wt % or more and 55 wt % or less relative to the total amount of the composition.

Methods and composition for cell-based therapy as well as somatostatin receptor-based therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a signaling defective somatostatin receptor mutant are described. Furthermore, the invention provides compositions and methods involve a somatostatin constitutively active somatostatin receptor mutant.

Methods and composition for cell-based therapy as well as somatostatin receptor-based therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a signaling defective somatostatin receptor mutant are described. Furthermore, the invention provides compositions and methods involve a somatostatin constitutively active somatostatin receptor mutant.

Mixed allergen compositions of two or more different allergens are provided. In some instances, the mixed allergen compositions include: a nut allergen; an animal allergen; and at least one of: a non-nut plant allergen; a biotic agent; and a vitamin. Also provided are methods of administering the mixed allergen compositions to a subject. The mixed allergen compositions find use in a variety of applications, including health maintenance, immune balance, gut balance, immune support, health improvement and therapeutic applications.

Mixed allergen compositions of two or more different allergens are provided. In some instances, the mixed allergen compositions include: a nut allergen; an animal allergen; and at least one of: a non-nut plant allergen; a biotic agent; and a vitamin. Also provided are methods of administering the mixed allergen compositions to a subject. The mixed allergen compositions find use in a variety of applications, including health maintenance, immune balance, gut balance, immune support, health improvement and therapeutic applications.

An orally ingestible contraceptive composition for a pig or rodent is provided. The exemplary composition comprises 0.005 to 1.4 wt. % free gossypol and non-free-gossypol matter. The non-free-gossypol matter comprises a bulk feed component, a pig attractant, a flavored component, or any combination thereof. An assembly may include an orally ingestible contraceptive composition for a pig or rodent and a package. A system for delivering an orally ingestible contraceptive composition to a pig or rodent may include the composition and an apparatus configured to permit pigs or rodents to eat the composition and inhibit other animals from eating the composition. A method for delivering an orally ingestible contraceptive composition to a pig or rodent includes making the composition available to the pig.

An orally ingestible contraceptive composition for a pig or rodent is provided. The exemplary composition comprises 0.005 to 1.4 wt. % free gossypol and non-free-gossypol matter. The non-free-gossypol matter comprises a bulk feed component, a pig attractant, a flavored component, or any combination thereof. An assembly may include an orally ingestible contraceptive composition for a pig or rodent and a package. A system for delivering an orally ingestible contraceptive composition to a pig or rodent may include the composition and an apparatus configured to permit pigs or rodents to eat the composition and inhibit other animals from eating the composition. A method for delivering an orally ingestible contraceptive composition to a pig or rodent includes making the composition available to the pig.